8-K
filed January 8, 2024, 6:59 PM ET
ticker DXCM
CIK 0001093557
earnings
confidence high
sentiment positive
materiality 0.80
DexCom reports preliminary Q4 revenue ≥$1.03B (+26% YoY); FY2024 guidance $4.15-4.35B
DEXCOM INC
2023-FY EPS reported
$1.30
revenue$3,622,300,000
- Preliminary Q4 2023 revenue at least $1.030B, up 26% YoY; FY2023 revenue ~$3.62B (+24%).
- FY2024 revenue guidance $4.15-4.35B, representing organic growth of 16-21%.
- Non-GAAP gross profit margin guidance 63-64% for FY2024; operating margin ~20%.
- Submitted Stelo glucose sensor for type 2 non-insulin users to FDA; expected U.S. launch summer 2024.
- U.S. Q4 revenue ~$765M (+26% YoY); international ~$265M (+27% YoY).
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
DEXCOM INC reported the fourth quarter ended December 31, 2023 results: revenue $1.030 billion.
- Period
- the fourth quarter ended December 31, 2023
- Revenue
- $1.030 billion
- Result
- preliminary results
Exact text from the filing
preliminary, unaudited revenue for the fourth quarter ended December 31, 2023 is expected to be at least $1.030 billion
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
DEXCOM INC reported fiscal year 2024 results: revenue $4.15 billion to $4.35 billion. Guidance initiated.
- Period
- fiscal year 2024
- Revenue
- $4.15 billion to $4.35 billion
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
For 2024, Dexcom currently anticipates total revenue of approximately $4.15 billion to $4.35 billion
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
DEXCOM INC reported fiscal year 2023 results: revenue $3.62 billion.
- Period
- fiscal year 2023
- Revenue
- $3.62 billion
- Result
- preliminary results
Exact text from the filing
For fiscal year 2023, total preliminary, unaudited revenue is expected to be approximately $3.62 billion
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.